ABCC8 and type 2 diabetes mellitus: Glibenclamide is a second-generation sulfonylurea developed for type 2 diabetes targeting the SUR1-TRPM4 channel, and glibenclamide inhibits SUR1-TRPM4 channel upregulation after CNS damage.